Evidence of immune response to BNT162b2 COVID-19 vaccine in systemic lupus erythematosus patients treated with Belimumab.

Ilaria Schiavoni,Eleonora Olivetta,Francesco Natalucci,Giulio Olivieri,Alessandra Lo Presti,Giorgio Fedele,Paola Stefanelli,Fulvia Ceccarelli,Fabrizio Conti

Lupus（2023）

引用 6|浏览21

暂无评分

摘要

BLM does not impair humoral response to primary BNT162b2 SARS-CoV-2 vaccination. During the follow-up, a decline in antibody levels is evident and the third dose is crucial to increase the specific immune response. Finally, we observed a recall T-cell response to the Spike antigen 6 months after the first vaccination cycle.

查看译文

关键词

BNT162b2 SARS-CoV-2 vaccine,Belimumab,systemic lupus erythematosus

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要